Compass Therapeutics, Inc. (CMPX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Compass Therapeutics, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $219.59M in total assets against $22.80M in total liabilities.
Key ratios (FY2025)
-33.8%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850.0K | $0 | — | — | — | — | — |
| Operating Income | -$72.84M | -$56.62M | -$50.36M | -$41.66M | -$81.88M | -$27.81M | -$34.05M | — |
| Net Income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.50M | -$34.74M | — |
| EPS (Diluted) | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 | — | — | — |
| Total Assets | $219.59M | $140.40M | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M | $25 |
| Total Liabilities | $22.80M | $15.17M | $8.34M | $18.01M | $13.68M | $11.97M | $19.11M | $34.6K |
| Shareholders' Equity | $196.79M | $125.23M | $148.54M | $181.64M | $140.08M | $39.95M | $11.27M | -$84.77M |
| Cash & Equivalents | $30.64M | $43.48M | $24.23M | $34.95M | $144.51M | $47.08M | $25.30M | — |
| Operating Cash Flow | -$49.14M | -$44.85M | -$40.62M | -$34.12M | -$19.67M | -$26.80M | -$31.74M | — |
| Capital Expenditures | $25.0K | $44.0K | $30.0K | $212.0K | $1.57M | $106.0K | $466.0K | — |
| Shares Outstanding | 178.32M | 137.82M | 127.67M | 126.30M | 100.83M | 51.22M | 7.03M | 5.00M |